Literature DB >> 17635382

Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial.

D Guyonnet1, O Chassany, P Ducrotte, C Picard, M Mouret, C-H Mercier, C Matuchansky.   

Abstract

BACKGROUND: Health-related quality of life (HRQoL) has been rarely evaluated as a primary endpoint in the assessment of the effect of probiotics on the irritable bowel syndrome (IBS). AIM: To study the effects of fermented milk containing Bifidobacterium animalis DN-173 010 and yoghurt strains on the IBS in a multicentre, double-blind, controlled trial.
METHODS: A total of 274 primary care adults with constipation-predominant IBS (Rome II) were randomized to consume for 6 weeks either the test fermented milk or a heat-treated yoghurt (control). HRQoL and digestive symptoms were assessed after 3 and 6 weeks on an intention-to-treat population of 267 subjects.
RESULTS: The HRQoL discomfort score, the primary endpoint, improved (P < 0.001) in both groups at weeks 3 and 6. The responder rate for the HRQoL discomfort score was higher (65.2 vs. 47.7%, P < 0.005), as was the decrease in bloating score [0.56 +/- (s.d.)1.01 vs. 0.31 +/- 0.87, P = 0.03], at week 3 in the test vs. the control group. In those subjects with <3 stools/week, stool frequency increased (P < 0.001) over 6 weeks in the test vs. control group.
CONCLUSIONS: This study suggests a beneficial effect of a probiotic food on discomfort HRQoL score and bloating in constipation-predominant IBS, and on stool frequency in subjects with <3 stools/week.

Entities:  

Mesh:

Year:  2007        PMID: 17635382     DOI: 10.1111/j.1365-2036.2007.03362.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  83 in total

1.  Acquired tolerance to oxidative stress in Bifidobacterium longum 105-A via expression of a catalase gene.

Authors:  Jianlong He; Kouta Sakaguchi; Tohru Suzuki
Journal:  Appl Environ Microbiol       Date:  2012-02-03       Impact factor: 4.792

2.  Do probiotics improve symptoms in patients with irritable bowel syndrome?

Authors:  Peter J Whorwell
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

Review 3.  Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.

Authors:  Michael Camilleri; Lin Chang
Journal:  Gastroenterology       Date:  2008-10-09       Impact factor: 22.682

Review 4.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

5.  The human microbiome and probiotics: implications for pediatrics.

Authors:  Michael H Hsieh; James Versalovic
Journal:  Curr Probl Pediatr Adolesc Health Care       Date:  2008 Nov-Dec

6.  Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women.

Authors:  Yue-Xin Yang; Mei He; Gang Hu; Jie Wei; Philippe Pages; Xian-Hua Yang; Sophie Bourdu-Naturel
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

7.  A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial.

Authors:  Solveig C Ligaarden; Lars Axelsson; Kristine Naterstad; Stian Lydersen; Per G Farup
Journal:  BMC Gastroenterol       Date:  2010-02-10       Impact factor: 3.067

8.  Probiotic treatment of irritable bowel syndrome in children.

Authors:  U Martens; P Enck; E Zieseniss
Journal:  Ger Med Sci       Date:  2010-03-02

9.  Gut inflammation in chronic fatigue syndrome.

Authors:  Shaheen E Lakhan; Annette Kirchgessner
Journal:  Nutr Metab (Lond)       Date:  2010-10-12       Impact factor: 4.169

Review 10.  The gastrointestinal microbiome: a malleable, third genome of mammals.

Authors:  Ian M Carroll; David W Threadgill; Deborah S Threadgill
Journal:  Mamm Genome       Date:  2009-07-21       Impact factor: 2.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.